TY - JOUR
T1 - Marburg virus Angola infection of rhesus macaques
T2 - Pathogenesis and treatment with recombinant nematode anticoagulant protein c2
AU - Geisbert, Thomas W.
AU - Daddario-DiCaprio, Kathleen M.
AU - Geisbert, Joan B.
AU - Young, Howard A.
AU - Formenty, Pierre
AU - Fritz, Elizabeth A.
AU - Larsen, Tom
AU - Hensley, Lisa E.
N1 - Funding Information:
Financial support: Defense Threat Reduction Agency and the Medical Chemical/ Biological Defense Research Program, US Army Medical Research and Material Command (project 02-4-4J-081). Supplement sponsorship is detailed in the Acknowledgments.
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Filoviruses: Recent Advances and Future Challenges,” sponsored by the Public Health Agency of Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH2A, Smith Carter, Hemisphere Engineering, Crucell, and the International Centre for Infectious Diseases.
PY - 2007/11/15
Y1 - 2007/11/15
N2 - Background. The procoagulant tissue factor (TF) is thought to play a role in the coagulation disorders that characterize filoviral infections. In this study, we evaluated the pathogenesis of lethal infection with the Angola strain of Marburg virus (MARV-Ang) in rhesus macaques and tested the efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2), an inhibitor of TF/factor VIIa, as a potential treatment. Methods. Twelve rhesus macaques were challenged with a high dose (1000 pfu) of MARV-Ang. Six macaques were treated with rNAPc2, and 6 macaques served as control animals. Results. All 6 control animals succumbed to MARV-Ang challenge by day 8 (mean, 7.3 days), whereas 5 of 6 rNAPc2-treated animals died on day 9 and 1 rNAPc2-treated animal survived. The disease course for MARV-Ang infection appeared to progress more rapidly in rhesus macaques than has been previously reported for other strains of MARV. In contrast to Ebola virus (EBOV) infection in macaques, up-regulation of TF was not as striking, and deposition of fibrin was a less prominent pathologic feature of disease in these animals. Conclusions. These data show that the pathogenicity of MARV-Ang infection appears to be consistent with the apparent increased human virulence attributed to this strain. The apparent reduced efficacy of rNAPc2 against MARV-Ang infection, compared with its efficacy against EBOV infection, appears to be associated with differences in TF induction and fibrin deposition.
AB - Background. The procoagulant tissue factor (TF) is thought to play a role in the coagulation disorders that characterize filoviral infections. In this study, we evaluated the pathogenesis of lethal infection with the Angola strain of Marburg virus (MARV-Ang) in rhesus macaques and tested the efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2), an inhibitor of TF/factor VIIa, as a potential treatment. Methods. Twelve rhesus macaques were challenged with a high dose (1000 pfu) of MARV-Ang. Six macaques were treated with rNAPc2, and 6 macaques served as control animals. Results. All 6 control animals succumbed to MARV-Ang challenge by day 8 (mean, 7.3 days), whereas 5 of 6 rNAPc2-treated animals died on day 9 and 1 rNAPc2-treated animal survived. The disease course for MARV-Ang infection appeared to progress more rapidly in rhesus macaques than has been previously reported for other strains of MARV. In contrast to Ebola virus (EBOV) infection in macaques, up-regulation of TF was not as striking, and deposition of fibrin was a less prominent pathologic feature of disease in these animals. Conclusions. These data show that the pathogenicity of MARV-Ang infection appears to be consistent with the apparent increased human virulence attributed to this strain. The apparent reduced efficacy of rNAPc2 against MARV-Ang infection, compared with its efficacy against EBOV infection, appears to be associated with differences in TF induction and fibrin deposition.
UR - http://www.scopus.com/inward/record.url?scp=38449090111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449090111&partnerID=8YFLogxK
U2 - 10.1086/520608
DO - 10.1086/520608
M3 - Article
C2 - 17940973
AN - SCOPUS:38449090111
SN - 0022-1899
VL - 196
SP - S372-S381
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - SUPPL. 2
ER -